Arav-Boger Ravit
Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins Hospital, Baltimore, MD, 21287-4933, USA.
Virus Genes. 2009 Apr;38(2):195-203. doi: 10.1007/s11262-008-0325-y. Epub 2009 Jan 13.
Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.
卡波西肉瘤相关疱疹病毒（KSHV）与三种不同的恶性肿瘤相关：卡波西肉瘤（KS）、原发性渗出性淋巴瘤和多中心性Castleman病。KSHV的治疗方法很大程度上是基于对其分子发病机制的理解而开发的。KSHV基因组已被完全测序，包含许多与人类调节基因具有同源性的基因，这些基因在KS的发展中可能具有重要意义。已经开发出针对由KSHV激活的信号通路的治疗策略。这篇综述描述了在KS患者中研究过的多类药理化合物，包括抗病毒药物、化疗药物以及与KSHV发病机制相关的新型药物。
